# 1. Financial Performance ## A. Key Figures * **Total Revenue:** **₹1,085 Cr** Q2 FY'26 (+8%) · **61:39** domestic:international mix H1 FY'26 * **EBITDA (ex. ESOP):** **₹319 Cr** Q2 FY'26 (+12%) · **₹649 Cr** H1 FY'26 (+13%) * **Net Profit:** **₹208 Cr** Q2 FY'26 (+19%) · **₹410 Cr** H1 FY'26 (+17%) * Gross Margin: **68.2%** Q2 FY'26 (+200 bps) · **29.4%** EBITDA margin Q2 FY'26 (+100 bps) * **Cash Flow & Balance Sheet:** **₹363 Cr** OCF H1 FY'26 · **₹939 Cr** net cash · **₹7 Cr** gross debt (as of Sep '25) ## B. Revenue Growth * **Volume-Price Synergy:** Revenue growth underpinned by balanced contribution from **volume** and **price**, with H1 seeing mid-single-digit volume expansion and high-single-digit pricing gains. * **Stable Geographic Mix:** Domestic market remains core, with international contribution holding steady at **39%** of H1 revenue. ## C. Profit Margins * **Margin Expansion Accelerates:** Gross and operating margins improved significantly on cost discipline, favorable mix, and pricing, despite flat reported gross margin percentage due to base effect. * **Sustained Profitability Uplift:** H1 EBITDA margin expanded **110 bps to 8%**, reflecting operating leverage and one-off normalization; net profit growth outpaced revenue, indicating strong earnings quality. * **ESOP Impact Clarified:** Non-cash ESOP charge of **₹10 Cr** per quarter; awards governed by SPA, not individual contracts, reducing execution risk. ## D. Cash Flow & Balance Sheet * **Robust Cash Generation:** Strong operating cash flow of **₹363 Cr** in H1 supports self-funded growth, even with higher cash tax outflow. * **Deleveraging Continues:** Gross debt halved to **₹7 Cr**; company maintains a fortress balance sheet with **₹939 Cr** in net cash, enabling strategic flexibility. * **Capex Discipline:** H1 net capex slightly reduced to **₹46 Cr**, signaling efficient capital allocation amid ongoing operations. --- # 2. Product & Therapy Performance ## A. Key Figures * **Rosuvastatin Revenue:** **₹104 Cr** (MAT Sep-25) (+58% from ₹66 Cr in MAT Sep-22) * **Chronic Portfolio Growth:** **>20%** YoY * **Ophthal Portfolio Growth:** **~16%** in covered markets (H1) * **API Revenue:** **₹22 Cr** (+₹3 Cr YoY) ## B. Chronic Portfolio * **Franchise Strength:** Rosuvastatin (Reserve) achieves **₹100 Cr+ revenue milestone**, with six chronic brands delivering sustained **double-digit growth momentum**. * **Mixed Segment Performance:** Chronic therapies show **strong double-digit growth**, but overall India business limited to **9%** due to **acute segment headwinds** affecting legacy brands like Rantac and Metrogyl. ## C. Acute Portfolio * **Seasonal Softness:** Acute segment faced a **muted Q2**, pressuring domestic growth, driven by **tough prior-year comparisons** and lower demand for Metrogyl and Rantac. ## D. Ophthal Segment * **Margin Inflection Ahead:** Ophthal segment set for **step-up in gross margins from 2027** following perpetual license trigger in Dec-26, expected to exceed current domestic business margins. * **Robust Commercial Traction:** Portfolio now at **₹17–18 Cr monthly run rate**, growing significantly above market pace, fueled by **new organic launches** and expanded prescriber coverage. * **Inventory Discipline:** Stock levels to remain **range-bound through H1 FY26**, supporting imported ophthal products and managing **high API cost volatility**. ## E. API Business * **Modest Expansion:** API category shows **modest revenue growth**, reflecting incremental progress in a smaller but strategic segment. --- # 3. Geography & Market Mix ## A. Key Figures * **Domestic Revenue:** **₹644 Cr** (+9%) * **US Quarterly Revenue:** **$10–12 Mn** ## B. Domestic Market * **Market Leadership Accelerating:** JB Pharma ranks as the fastest-growing among India’s top 25 pharma companies, with all major brands gaining share and **three now in IPM’s top 100**. * **Sustained Volume Outperformance:** Company continues to outpace Indian market volume growth by **3 percentage points**, despite near-term headwinds from seasonal and base effects. * **Strong Execution Premium:** Domestic business outperforms overall market growth by **300–400 bps**, reflecting effective commercial strategy and favorable category dynamics. ## C. US Performance * **Growth Rebound Expected:** US segment on track for recovery in H2, with revenue stabilizing within expected quarterly range. ## D. Russia CIS * **Resilient Regional Performance:** Russia CIS remains a strong contributor, supporting export formulation stability amid softer demand elsewhere. ## E. South Africa * **Strategic Market Pivot:** Reduced public tender participation in South Africa (from **65% to 35%**) reflects deliberate shift toward higher-margin private market expansion. --- # 4. Segment & Business Lines ## A. Key Figures * **International Business Revenue:** **₹441 Cr** (+7%) * **CDMO Revenue:** **₹113 Cr** (+20%) * **International Formulations Revenue:** **₹306 Cr** (+2%) * **Domestic Formulations Revenue:** **₹644 Cr** (+9%) ## B. CDMO Growth * **Robust CDMO Momentum:** CDMO segment delivered strong double-digit growth, driving international revenue expansion and tracking toward full-year guidance of mid-teens growth. * **Strategic Project Pipeline:** Multiple marquee projects underway, reinforcing confidence in sustained momentum and growth trajectory beyond current year. ## C. International Formulations * **Mixed International Performance:** International formulations showed moderate growth, supported by strong Russia performance, with recovery expected in H2. * **Domestic Outperformance:** Domestic formulations grew at a faster pace than the IPM market, reflecting competitive market share gains. ## D. Field Force Productivity * **Stable Field Force Size:** Active MR base maintained at **~2,400**, with no recent expansion, reflecting focus on productivity over headcount. * **Productivity Guidance Clarified:** MR productivity is trending in line with guidance at **₹5 lakh per MR**, with future expansion contingent on performance. ## E. Brand Market Share * **API Business Strategy:** API segment focused on optimizing existing portfolio and captive demand, targeting a stable quarterly run rate of **₹25 Cr** without reliance on new launches. --- # 5. Manufacturing & Capacity ## A. Key Figures * **Capex:** **₹100 Cr** full-year projection · **₹60–65 Cr** maintenance portion ## B. Capex Plan * **Greenfield Expansion Accelerates:** Majority of growth capex directed toward new IV line, expected to be commissioned within two months, enhancing manufacturing scale. --- # 6. Pricing & Regulatory Risks ## A. Key Figures * **Price Growth:** **7%** domestic H1 · **6%** domestic Q2 ## B. GST Impact * **No Material GST Disruption:** Domestic business experienced no material impact from new GST rates, with reported growth unaffected by channel dynamics. * **Selective Price Implementation:** Price hikes were applied on a **product-to-product basis**, varying by brand-specific timing and strategy. ## C. US Base Comparison * **High Base Weighs on US Growth:** US business faces challenging prior-year comparisons due to strong performance and elevated supply, though demand remains stable. * **No Pricing Pressure:** Despite tough comps, there is **no price reduction or pricing pressure** in the US market, supporting margin integrity. --- # 7. Guidance & Outlook ## A. Key Figures * **Domestic Revenue Growth Guidance:** **12%–14%** full-year FY'26 * **Gross Margin Guidance:** **67%–69%** (current: **68%**) * **EBITDA Margin Guidance:** **27%–29%** ## B. Revenue Targets * **H2 Growth Momentum:** Top-line expansion expected to accelerate in H2, underpinned by **strong order book** and chronic segment strength. * **Strategic Focus:** Growth to be driven by domestic markets and CDMO segment, reflecting targeted portfolio leverage. ## C. Margin Forecast * **Margin Resilience:** Gross and EBITDA margins tracking within guided bands, demonstrating pricing discipline and operational control. ## D. Productivity Goal * **Field Force Discipline:** Management has set an internal productivity benchmark of **INR 8 lakh** per representative; future expansions contingent on achieving this threshold.